Cargando…

Cost analysis of extended half-life recombinant factor IX products in the treatment of haemophilia B in Italy: an update

Haemophilia B (HB) is a rare disease which may lead to chronic disabling arthropathy, resulting in a significant clinical, social and economic impact. In recent years, new extended half-life (EHL) factor IX concentrates produced by recombinant technology (rFIX) have been developed. They have shown s...

Descripción completa

Detalles Bibliográficos
Autores principales:	Aiello, Andrea, Mancuso, Maria E., Leone, Serena, Rossi, Letizia, Cioni, Lorenzo, Teruzzi, Cristina
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AboutScience 2022
Materias:	Short Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9768593/ https://www.ncbi.nlm.nih.gov/pubmed/36628322 http://dx.doi.org/10.33393/grhta.2022.2331

Ejemplares similares

Budget impact analysis of extended half-life recombinant factor IX (rFIXFc) in the treatment of haemophilia B
por: Aiello, Andrea, et al.
Publicado: (2020)

Updates in clinical trial data of extended half-life recombinant factor IX products for the treatment of haemophilia B
por: Mahlangu, Johnny N.
Publicado: (2018)

Outcome of Clinical Trials with New Extended Half-Life FVIII/IX Concentrates
por: Mancuso, Maria Elisa, et al.
Publicado: (2017)

Biodistribution of recombinant factor IX, extended half-life recombinant factor IX Fc fusion protein, and glycoPEGylated recombinant factor IX in hemophilia B mice
por: van der Flier, Arjan, et al.
Publicado: (2023)

Surgical outcomes in patients with haemophilia A or B receiving extended half‐life recombinant factor VIII and IX Fc fusion proteins: Real‐world experience in the Nordic countries
por: Lehtinen, Anna‐Elina, et al.
Publicado: (2022)

Budget impact analysis of anakinra in the treatment of familial Mediterranean fever in Italy
por: Aiello, A, et al.
Publicado: (2023)

Postmarketing safety and effectiveness of recombinant factor IX (nonacog alfa) in Japanese patients with haemophilia B
por: Fukutake, Katsuyuki, et al.
Publicado: (2019)

IDEAL study: A real‐world assessment of pattern of use and clinical outcomes with recombinant coagulation factor IX albumin fusion protein (rIX‐FP) in patients with haemophilia B in Italy
por: Tagliaferri, Annarita, et al.
Publicado: (2022)

Recombinant factor VIII Fc for the treatment of haemophilia A
por: Hermans, Cedric, et al.
Publicado: (2021)

Half-life–extended recombinant coagulation factor IX–albumin fusion protein is recycled via the FcRn-mediated pathway
por: Chia, Jenny, et al.
Publicado: (2018)

Population Pharmacokinetic Modelling of Recombinant Factor IX Fc Fusion Protein (rFIXFc) in Patients with Haemophilia B
por: Diao, Lei, et al.
Publicado: (2014)

In silico comparison of pharmacokinetic properties of three extended half-life factor IX concentrates
por: Preijers, Tim, et al.
Publicado: (2021)

Treatment and Prevention of Bleeds in Haemophilia Patients with Inhibitors to Factor VIII/IX
por: Rocino, Angiola, et al.
Publicado: (2017)

Modified Factor VIII and Factor IX recombinant products
por: Santagostino, Elena, et al.
Publicado: (2018)

Bleeding outcomes and factor utilization after switching to an extended half-life product for prophylaxis in haemophilia A in Austria
por: Ay, Cihan, et al.
Publicado: (2021)

Real-World Utilisation and Bleed Rates in Patients with Haemophilia B Who Switched to Recombinant Factor IX Fusion Protein (rIX-FP): A Retrospective International Analysis
por: Hermans, Cedric, et al.
Publicado: (2020)

Fusion of engineered albumin with factor IX Padua extends half‐life and improves coagulant activity
por: Lombardi, Silvia, et al.
Publicado: (2021)

GlycoPEGylated recombinant factor IX for hemophilia B in context
por: Santagostino, Elena, et al.
Publicado: (2018)

Budget impact analysis of the use of extended half-life recombinant factor VIII (efmoroctocog alfa) for the treatment of congenital haemophilia a: the Italian National Health System perspective
por: Lorenzoni, Valentina, et al.
Publicado: (2018)

Extended half-life factor IX prophylaxis up to every 21 days in hemophilia B: a longitudinal analysis of the efficacy and safety in selected adult patients
por: Pabinger, Ingrid, et al.
Publicado: (2023)

Performance of factor IX extended half‐life product measurements in external quality control assessment programs
por: Nederlof, Angelique, et al.
Publicado: (2020)

Measurement of extended half-life recombinant FVIII molecules: In vitro and ex vivo evidence of relevant assay discrepancies
por: Lancellotti, Stefano, et al.
Publicado: (2023)

Sustained high trough factor IX activity levels with continued use of rIX‐FP in adult and paediatric patients with haemophilia B
por: Gill, Joan C., et al.
Publicado: (2019)

High adherence to prophylaxis regimens in haemophilia B patients receiving rIX‐FP: Evidence from clinical trials and real‐world practice
por: Mancuso, Maria Elisa, et al.
Publicado: (2020)

Real‐world data demonstrate improved bleed control and extended dosing intervals for patients with haemophilia B after switching to recombinant factor IX Fc fusion protein (rFIXFc) for up to 5 years
por: Shapiro, Amy, et al.
Publicado: (2020)

Health‐related quality of life in paediatric haemophilia B patients treated with rIX‐FP
por: von Mackensen, Sylvia, et al.
Publicado: (2018)

LongHest project: A prospective, observational study of extended half‐life treatment in the musculoskeletal health of patients with severe haemophilia A
por: Cuesta‐Barriuso, Rubén, et al.
Publicado: (2022)

Real-World Analysis of Dispensed IUs of Coagulation Factor IX and Resultant Expenditures in Hemophilia B Patients Receiving Standard Half-Life Versus Extended Half-Life Products and Those Switching from Standard Half-Life to Extended Half-Life Products
por: Tortella, Bartholomew J., et al.
Publicado: (2018)

Recombinant proteins in therapeutics: haemophilia treatment as an example
por: Liras, Antonio
Publicado: (2008)

Epidemiology & social costs of haemophilia in India
por: Kar, Anita, et al.
Publicado: (2014)

Monitoring standard and extended half‐life products in hemophilia: Assay discrepancies for factor VIII and IX in pre‐ and postinfusion samples
por: Augustsson, Cecilia, et al.
Publicado: (2020)

An Update on Laboratory Diagnostics in Haemophilia A and B
por: Müller, Jens, et al.
Publicado: (2022)

Successful Hemostasis with Extended Half-life Recombinant Factor VIII in Circumcision
por: Koç, Başak, et al.
Publicado: (2020)

Real Life Population Pharmacokinetics Modelling of Eight Factors VIII in Patients with Severe Haemophilia A: Is It Always Relevant to Switch to an Extended Half-Life?
por: Allard, Quentin, et al.
Publicado: (2020)

Results of a phase I/II open-label, safety and efficacy trial of coagulation factor IX (recombinant), albumin fusion protein in haemophilia B patients
por: Martinowitz, U, et al.
Publicado: (2015)

In silico evaluation of limited sampling strategies for individualized dosing of extended half-life factor IX concentrates in hemophilia B patients
por: Preijers, T., et al.
Publicado: (2021)

Perioperative haemostasis with full‐length, PEGylated, recombinant factor VIII with extended half‐life (rurioctocog alfa pegol) in patients with haemophilia A: Final results of a multicentre, single‐arm phase III trial
por: Gruppo, Ralph, et al.
Publicado: (2019)

Cost of illness of urothelial bladder cancer in Italy
por: Gerace, Claudio, et al.
Publicado: (2017)

Case report: successful perioperative management of patients with haemophilia A using an extended half-life factor VIII (Efmoroctocog alfa) during neurosurgical procedures
por: Kocher, Florian, et al.
Publicado: (2021)

P1633: OUTCOME OF SURGICAL INTERVENTIONS IN PATIENTS WITH HAEMOPHILIA A AND B TREATED WITH EXTENDED HALF-LIFE (EHL) FACTOR CONCENTRATES IN A SINGLE CENTRE
por: Vaide, Ines, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_h35ao591umbpblru23j3fk1tem